Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients

TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) found XARELTO® showed non-inferiority for the composite outcome of recurrent VTE or any bleeding resulting in hospitalization for treatment of patients with CAT. Janssen and its development partner Bayer will feature results in an oral presentation on Sunday, December 11, 2022, at 1:15 p.m. CT at the American Society of Hematology (ASH) 64th Annual Meeting and Exposition. The study further adds to the robust real-world evidence for XARELTO®, with over 300,000 patients having been evaluated in published real-world research since its initial approval in the U.S. in 2011.“The OSCAR study provides robust, real-world evidence in patients with CAT and builds upon previous XARELTO® safety and efficacy data observed in both clinical practice and in randomized clinical trials. The data show XARELTO® can be an effecti...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news